Thatcher N, Stout R, Smith D B, Grötte G, Winson M, Bassett H, Carroll K B
Br J Cancer. 1985 Sep;52(3):327-32. doi: 10.1038/bjc.1985.197.
Fifty-five patients with inoperable but limited stage small cell carcinoma of the bronchus and a further 15 patients with contra lateral neck nodes, pleural effusions and marrow involvement were entered into the study and treated. The 3 month treatment regimen comprised 3 courses of etoposide with cyclophosphamide at 2.5 gm-2 followed by methotrexate and radiotherapy, no maintenance treatment was given. The complete response rate in the total patient group was 54% and the partial response rate 21%. The median survival was 11 months for the 70 patients, 15 months for the complete responders, and those patients with a bronchoscopically confirmed complete response survived significantly longer. There was no significant difference between the patients with strictly limited stage disease and those in the broader category. Eight patients are tumour free and alive one year or more after the end of treatment. The median followup is 17 months. Twenty-four patients were delayed 1-2 weeks during treatment because of chemotherapy induced toxicity. Six patients died probably of infection associated with leucopaenia. The majority of the patients' Karnofsky performance improved with the treatment as did their breathlessness assessed on a respiratory score. The short intensive chemotherapy regimen of 3 months produced similar results to those following more prolonged treatment regimens.
55例患有无法手术但处于局限期的支气管小细胞癌患者以及另外15例有对侧颈部淋巴结、胸腔积液和骨髓受累的患者进入本研究并接受治疗。3个月的治疗方案包括3个疗程的依托泊苷与环磷酰胺（2.5克/平方米），随后是甲氨蝶呤和放疗，未给予维持治疗。整个患者组的完全缓解率为54%，部分缓解率为21%。70例患者的中位生存期为11个月，完全缓解者为15个月，经支气管镜证实完全缓解的患者存活时间显著更长。严格局限期疾病患者与更广泛类别患者之间无显著差异。8例患者在治疗结束后1年或更长时间无瘤存活。中位随访时间为17个月。24例患者在治疗期间因化疗引起的毒性反应而延迟1 - 2周。6例患者可能死于与白细胞减少相关的感染。大多数患者的卡诺夫斯基表现评分以及根据呼吸评分评估的呼吸困难程度随着治疗而改善。3个月的短期强化化疗方案产生的结果与更长疗程治疗方案的结果相似。
